Table 3.
Bisphosphonate (Dose, Route of Administration) | Reduction in Risk of SRE | Relative Risk (95% CI) |
---|---|---|
Zoledronic acid, 4 mg IV | 41% | 0.59 (0.42–0.82) |
Pamidronate, 90 mg IV | 23% | 0.77 (0.69–0.87) |
Ibandronate, 6 mg IV | 18% | 0.82 (0.67–1.00) |
Ibandronate, 50 mg PO | 14% | 0.86 (0.73–1.02) |
Clodronate, 1600 mg PO | 16% | 0.84 (0.72–0.98) |
Abbreviations: IV, intravenous; PO, by mouth; SRE, skeletal-related event.
Data from Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;CD003474.